SEARCH:   Advanced

Blood, 15 April 2008, Vol. 111, No. 8, pp. 4048-4054. Prepublished online as a Blood First Edition Paper on February 6, 2008; DOI 10.1182/blood-2007-09-111708. This Article Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2007-09-111708v1 111/8/4048    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Thompson, J. A Articles by Fefer, A. Search for Related Content PubMed PubMed Citation Articles by Thompson, J. A Articles by Fefer, A. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted September 11, 2007 Accepted January 17, 2008 Total body irradiation, etoposide, cyclophosphamide and autologous peripheral blood stem cell transplantation followed by randomization to therapy with Interleukin-2 versus observation for patients with non-Hodgkin's lymphoma: results of a phase III randomized trial by the Southwest Oncology Group (SWOG 9438) John A Thompson*, Richard I Fisher, Michael LeBlanc, Stephen J. Forman, Oliver W. Press, Joseph M Unger, Auayporn P Nademanee, Patrick J Stiff, Stephen H Petersdorf, and Alexander Fefer Puget Sound Oncology Consortium, Seattle, WA, United States James P Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, NY, United States Statistical Center, Southwest Oncology Group, Seattle, WA, United States Hematology and Hematopoietic Stem Cell Transplantation, City of Hope National Medical Center, Duarte, CA, United States Cardinal Bernardin Cancer Center, Loyola University Stritch School of Medicine, Maywood, IL, United States * Corresponding author; email: jat{at}u.washington.edu. To determine the effect of post-transplant immunotherapy with IL-2 on the progression-free survival (PFS) and overall survival (OS) of patients with non-Hodgkin's lymphoma (NHL) after autologous stem cell transplantation (PBSCT), patients with previously treated NHL were treated with cyclophosphamide, etoposide, total body irradiation (TBI) and PBSCT. Twenty-eight to 80 days after PBSCT, patients were randomized to IL-2 versus observation. Three hundred seventy-six eligible patients were registered (with 4-year PFS of 34% and 4-year OS of 52%) and 194 eligible patients were randomized to continuous infusion intravenous IL-2 (9 million units /m2/day for four days followed five days later by 1.6 million units/m2/day for 10 days) versus observation. In randomized patients, there was no significant difference in PFS (hazard ratio of IL-2 to observation=0.90; p=0.56) nor in OS (hazard ratio of IL-2 to observation=0.88; p=0.55). There were no deaths related to IL-2 treatment. Grade IV IL-2-related toxicities (n=14) were reversible in all cases. These results confirm earlier SWOG findings that cyclophosphamide, etoposide, TBI and PBSCT can be administered to patients with relapsed/refractory NHL with encouraging PFS and OS. Post-transplant IL-2 given at this dose and schedule of administration had no significant effect on post-transplant PFS or OS. This study is registered at www.ClinicalTrials.gov as NCT00002649. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020